
GSK Announces Priority Review and Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Bepirovirsen in Chronic Hepatitis B
GSK Reports U.S. Food and Drug Administration Grants Breakthrough Therapy Designation and Priority Review Acceptance for Bepirovirsen in Chronic Hepatitis B as Potential First-in-Class Treatment Ionis Pharmaceuticals and its partner…












